Advertisement

Pharmacologic Strategies for the Prevention of Stroke in Patients With Atrial Fibrillation

  • Greg Flaker
  • Richard Weachter
Arrhythmia

Opinion statement

Stroke is a dreaded complication of atrial fibrillation. In the past, preventive therapy included aspirin and oral anticoagulation. Selected patients who are not suitable for oral anticoagulation may benefit from the addition of clopidogrel with aspirin. This combination, when compared with aspirin, offers a reduced risk of stroke at a cost of more major bleeding. We use this therapy in patients with atrial fibrillation who have unstable coronary syndromes or in patients who receive coronary artery stents who are not good candidates for “triple therapy” with aspirin, clopidogrel, and warfarin. The duration of therapy is tempered by many variables. In the case of coronary stents, we ask the interventionalist to consider a bare metal stent to shorten the duration of need for clopidogrel plus aspirin. After several months of combination therapy, we stop this therapy and begin warfarin therapy. Dabigatran is commercially available in the United States. In patients who have difficult to control International Normalized Ratio (INR) values or who do not wish to have regular coagulation monitoring, dabigatran offers a huge advantage. The benefit seems less if the INR is consistently within range. We are impressed with the superior reduction in stroke and systemic embolism with 150 mg of dabigatran twice daily compared to warfarin and also its low risk of intracranial hemorrhage. The results of clinical trials involving factor Xa agents are now being presented. How these agents fit into the marketplace remains to be seen but they will offer clinicians additional therapy for stroke prevention in atrial fibrillation.

Keywords

Atrial Fibrillation Warfarin Clopidogrel International Normalize Ratio Dabigatran 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Disclosure

G. Flaker has received consulting fees from Sanofi Aventis and Bristol-Myers Squibb. He has received support for travel to meetings from Boehringer Ingelheim and Bristol-Myers Squibb, and his institution has received grant money from Boehringer Ingelheim and Bristol-Myers Squibb. R. Weachter reports no potential conflict of interest relevant to this article.

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: •• Of major importance

  1. 1.
    Hart RG, Lesly AP, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Int Med. 2007;146(12):857–67.PubMedGoogle Scholar
  2. 2.
    Laupacis A, Albers G, Dunn M, Feinberg W. Antithrombotic therapy in atrial fibrillation. Chest. 1992;102(suppl):426S–33S.PubMedCrossRefGoogle Scholar
  3. 3.
    Kumagai K, Fukunami M, Ohmori M, et al. Increased intracardiovascular clotting in patients with chronic atrial fibrillation. J Am Coll Cardiol. 1990;16:377–80.PubMedCrossRefGoogle Scholar
  4. 4.
    Gustafsson C, Blomback M, Britton M, Hamsten A, Svensson J. Coagulation factors and the increased risk of stroke in nonvalvular atrial fibrillation. Stroke. 1990;21:47–51.PubMedCrossRefGoogle Scholar
  5. 5.
    Lip GY, Lowe GD, Rumley A, Dunn FG. Increased markers of thrombogenesis in chronic atrial fibrillation: effects of warfarin treatment. Br Heart J. 1995;73:527–33.PubMedCrossRefGoogle Scholar
  6. 6.
    Asakura H, Hifumi S, Jokaji H, et al. Prothrombin fragment F1+2 and thrombin-antithrombin III complex are useful markers of the hypercoagulable state in atrial fibrillation. Blood Coagul Fibrinolysis. 1992;3:469–73.PubMedGoogle Scholar
  7. 7.
    Kamath S, Blann AD, Chin BS, et al. A study of platelet activation in atrial fibrillation and the effects of antithrombotic therapy. Eur Heart J. 2002;23:1788–95.PubMedCrossRefGoogle Scholar
  8. 8.
    Heeringa J, Conway DS, van der Kuip DA, et al. A longitudinal population-based study of prothrombotic factors in elderly subjects with atrial fibrillation: the Rotterdam Study 1990–1999. J Thromb Haemost. 2006;4:1944–9.PubMedCrossRefGoogle Scholar
  9. 9.
    Feng D, D’Agostino RB, Silbershatz H, et al. Hemostatic state and atrial fibrillation (The Framingham Offspring Study). Amer J Cardiol. 2001;87:168–71.PubMedCrossRefGoogle Scholar
  10. 10.
    Lip GYH, Lip PL, Zarifis J, et al. Fibrin D-dimer and beta-thromboglobulin as markers of thrombogenesis and platelet activation in atrial fibrillation. Effects of introducing ultra-low-dose of warfarin and aspirin. Circulation. 1996;94:425–31.PubMedGoogle Scholar
  11. 11.
    Kamath S, Blann AD, Chin BS, Lip GY. A prospective randomized trial of aspirin-clopidogrel combination therapy and dose-adjusted warfarin on indices of thrombogenesis and platelet activation in atrial fibrillation. J Am Coll Cardiol. 2002;40:484–90.PubMedCrossRefGoogle Scholar
  12. 12.
    Sadangara T, Sadanaga M, Ogawa S. Evidence that d-Dimer levels predict subsequent thromboembolic and cardiovascular events in patients with atrial fibrillation during oral anticoagulant therapy. JACC. 2010;55:2225–31.Google Scholar
  13. 13.
    Feinberg WM, Pearce LA, Hart RG, et al. Markers of thrombin and platelet activity in patients with atrial fibrillation: correlation with stroke among 1531 participants in the stroke prevention in atrial fibrillation III study. Stroke. 1999;30:2547–53.PubMedCrossRefGoogle Scholar
  14. 14.
    Connolly S, Pogue J, Hart R, et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet. 2006;367:1903–12.PubMedCrossRefGoogle Scholar
  15. 15.••
    Connolly SJ, Pogue J, Hart RG, et al.: Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med 2009;360:2066–78.PubMedCrossRefGoogle Scholar
  16. 16.
    2011 ACCF/AHA/HRS Focused Update on the Management of Patients with Atrial Fibrillation (Updating the 2006 Guideline)ACC/AHA guidelines. JACC 2011;57:223–42.Google Scholar
  17. 17.
    Executive Steering Committee on behalf of the SPORTIF III Investigators. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet. 2003;362:1691–8.CrossRefGoogle Scholar
  18. 18.
    SPORTIF Executive Steering Committee for the SPORTIF V Investigators. Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. JAMA. 2005;293(6):690–8.CrossRefGoogle Scholar
  19. 19.••
    Connolly SJ, Ezekowitz MD, Yusuf S, et al.: Dabigatran versus warfarin in patients with atrial fibrillation. NEJM 2009;361(12):1139–202. Correction NEJM 2010;363:11875–6.PubMedCrossRefGoogle Scholar
  20. 20.
    Fiessinger JN, Huisman MV, Davidson BL, et al. Ximelagatran vs. low molecular weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized trial. JAMA. 2005;293:681–9.PubMedCrossRefGoogle Scholar
  21. 21.
    Shulman S, Wahlander K, Lundstrom T, THRIVE III Investigators, et al. Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran. N Engl J Med. 2003;248:1713–21.CrossRefGoogle Scholar
  22. 22.
    Wallentin L, Wilcox R, Weaver W, et al. Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomized controlled trial. Lancet. 2003;362(9386):789–97.PubMedCrossRefGoogle Scholar
  23. 23.
    The Direct Thrombin Inhibitors Investigators. Direct thrombin inhibitors in acute coronary syndromes: principal results of a meta-analysis based on individual patients’ data. Lancet. 2002;359(9303):294–302.CrossRefGoogle Scholar
  24. 24.
    Eriksson BI, Dahl OE, Rosencher N, et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomized, double-blind, non-inferiority trial. Lancet. 2007;370(9591):949–55.PubMedCrossRefGoogle Scholar
  25. 25.
    Eriksson BI, Dahl OE, Rosencher N, et al. Oral dabigatrann etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolisms after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost. 2007;5(11):2178–85.PubMedCrossRefGoogle Scholar
  26. 26.
    The RE-MOBILIZE Writing committee. The oral thrombin inhibitor dabigatran etexilate vs. the North American enoxaparin regimen for the prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty. 2009;24(1):1–9.CrossRefGoogle Scholar
  27. 27.
    Stangier J, Rathgen K, Stahle H, et al. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in health male subjects. Br J Clin Pharmacology. 2007;64(3):292–303.CrossRefGoogle Scholar
  28. 28.
    Freeman J, Zhu R, Owens DK et al. Cost Effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation. Annals Int Med 2010.Google Scholar
  29. 29.
    Wallentin L, Yusuf S, Ezekowitz MD, et al. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalized ration control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet. 2010;376:975–83.PubMedCrossRefGoogle Scholar
  30. 30.
    The AMADEUS Investigators. Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomized, open-label, non-inferiority trial. Lancet. 2008;371:315–21.CrossRefGoogle Scholar
  31. 31.
    Connolly SJ, Eikelboom J, Joyner C, et al. Apixaban in patients with atrial fibrillation unsuitable for vitamin K antagonists. New England J Feb 10, 2011;364:806–17.Google Scholar
  32. 32.
    The Executive Steering Committee, on behalf of the ROCKET AF Study Investigators. Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation: Rationale and design of the ROCKET AF study. Amer Heart J. 2010;159:340–7.CrossRefGoogle Scholar
  33. 33.
    ROCKET-AF. Presented at the American Heart Association meeting 2010.Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  1. 1.Division of Cardiovascular MedicineUniversity of Missouri-ColumbiaColumbiaUSA

Personalised recommendations